Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oncorus, Inc.ONCR · Entity 112213 | Interim CFO | May 09, 2023 | May 22, 2023 |
| Syndax Pharmaceuticals IncSNDX · Entity 4578 | Chief Accounting Officer | February 02, 2023 | February 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oncorus, Inc.
Report date May 09, 2023 · Filed May 22, 2023
This filing explicitly reported no securities owned.
Syndax Pharmaceuticals Inc
Report date February 02, 2023 · Filed February 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.55 · Expires 2033-02-02 | Direct | 17,000 |
Reported balance
After 2023-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-02 · Grant · Acquired 17,000 · Balance 17,000 F1: 1/48th of the shares subject to the option shall vest monthly over a four-year period. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option shall vest monthly over a four-year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2023 Filed Feb 3, 2023 21:58 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Options (Right to buy) · Derivative | 17,000 | $28.55 Strike: $28.55 | $485,350.00 |
DisclosureSEC source: 0001562180-23-000948 · primarydocument.xml · derivative · entry 1 Nolte Alexander · CIK 0001891979 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2033-02-02 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 22:31 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Options (Right to buy) · Derivative | 30,000 | $15.79 Strike: $15.79 | $473,700.00 |
DisclosureSEC source: 0001562180-22-001077 · primarydocument.xml · derivative · entry 3 Nolte Alexander · CIK 0001891979 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-02-02 F2 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 22:31 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 968 | $16.65 | $16,117.20 |
DisclosureSEC source: 0001562180-22-001077 · primarydocument.xml · nonDerivative · entry 2 Nolte Alexander · CIK 0001891979 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 22:31 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | OtherCommon Stock | 968 | $12.39 | $11,993.52 |
DisclosureSEC source: 0001562180-22-001077 · primarydocument.xml · nonDerivative · entry 1 Nolte Alexander · CIK 0001891979 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 968 F1 · kind: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 968 shares by the Reporting Person on 01/31/2022 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.